Tags

Type your tag names separated by a space and hit enter

Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.
Pediatr Infect Dis J. 2014 Nov; 33(11):1169-76.PI

Abstract

BACKGROUND

The aim of this study was to evaluate antibody persistence 5 years after primary vaccination with the quadrivalent meningococcal conjugate vaccines MenACWY-CRM or MenACWY-D and 2 years after a booster dose of MenACWY-CRM, in the context of a phase 3 study.

METHODS

Subjects (aged 19.2 ± 2.3 years) were assigned to 5 groups according to whether they had previously received primary vaccination (at 14.2 ± 2.2 years) with MenACWY-CRM (N = 131) or MenACWY-D (N = 76), a booster dose of MenACWY-CRM 3 years after primary vaccination with MenACWY-CRM (N = 44) or MenACWY-D (N = 31) or no vaccination (N = 107). The immunogenicity measures were percentages of subjects with serum bactericidal activity (hSBA) ≥ 1:8 for serogroups A, C, W and Y and hSBA geometric mean titers. Comparisons with age-matched, vaccine-naive subjects were performed.

RESULTS

A majority of subjects vaccinated 5 years previously maintained hSBA ≥ 1:8 against serogroups C, W and Y in the MenACWY-CRM (59%-82%) and MenACWY-D groups (54%-73%); this was lower for serogroup A in both groups. There was a decline in antibody titers after primary vaccination, especially in the first 2 years postprimary vaccination, with steady concentrations during the next 3 years. Two years after MenACWY-CRM booster vaccination the percentages of subjects with hSBA ≥ 1:8 ranged from 77% to 100% across serogroups and geometric mean titers were 2.5- to 8-fold higher than prebooster values across serogroups.

CONCLUSIONS

Booster vaccination with MenACWY-CRM elicited a robust immune response during the 2-year follow-up period, irrespective of previous vaccination.

Authors+Show Affiliations

From the *Kaiser Permanente Vaccine Study Center, Oakland, CA; †Primary Physicians Research, Pittsburgh, PA; ‡Kentucky Pediatric and Adult Research, Bardstown, KY; and §Novartis Vaccines, Cambridge, MA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24911896

Citation

Baxter, Roger, et al. "Antibody Persistence After Primary and Booster Doses of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents." The Pediatric Infectious Disease Journal, vol. 33, no. 11, 2014, pp. 1169-76.
Baxter R, Reisinger K, Block SL, et al. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents. Pediatr Infect Dis J. 2014;33(11):1169-76.
Baxter, R., Reisinger, K., Block, S. L., Percell, S., Odrljin, T., Dull, P. M., & Smolenov, I. (2014). Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents. The Pediatric Infectious Disease Journal, 33(11), 1169-76. https://doi.org/10.1097/INF.0000000000000438
Baxter R, et al. Antibody Persistence After Primary and Booster Doses of a Quadrivalent Meningococcal Conjugate Vaccine in Adolescents. Pediatr Infect Dis J. 2014;33(11):1169-76. PubMed PMID: 24911896.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents. AU - Baxter,Roger, AU - Reisinger,Keith, AU - Block,Stanley L, AU - Percell,Sandra, AU - Odrljin,Tatjana, AU - Dull,Peter M, AU - Smolenov,Igor, PY - 2014/6/10/entrez PY - 2014/6/10/pubmed PY - 2015/10/29/medline SP - 1169 EP - 76 JF - The Pediatric infectious disease journal JO - Pediatr Infect Dis J VL - 33 IS - 11 N2 - BACKGROUND: The aim of this study was to evaluate antibody persistence 5 years after primary vaccination with the quadrivalent meningococcal conjugate vaccines MenACWY-CRM or MenACWY-D and 2 years after a booster dose of MenACWY-CRM, in the context of a phase 3 study. METHODS: Subjects (aged 19.2 ± 2.3 years) were assigned to 5 groups according to whether they had previously received primary vaccination (at 14.2 ± 2.2 years) with MenACWY-CRM (N = 131) or MenACWY-D (N = 76), a booster dose of MenACWY-CRM 3 years after primary vaccination with MenACWY-CRM (N = 44) or MenACWY-D (N = 31) or no vaccination (N = 107). The immunogenicity measures were percentages of subjects with serum bactericidal activity (hSBA) ≥ 1:8 for serogroups A, C, W and Y and hSBA geometric mean titers. Comparisons with age-matched, vaccine-naive subjects were performed. RESULTS: A majority of subjects vaccinated 5 years previously maintained hSBA ≥ 1:8 against serogroups C, W and Y in the MenACWY-CRM (59%-82%) and MenACWY-D groups (54%-73%); this was lower for serogroup A in both groups. There was a decline in antibody titers after primary vaccination, especially in the first 2 years postprimary vaccination, with steady concentrations during the next 3 years. Two years after MenACWY-CRM booster vaccination the percentages of subjects with hSBA ≥ 1:8 ranged from 77% to 100% across serogroups and geometric mean titers were 2.5- to 8-fold higher than prebooster values across serogroups. CONCLUSIONS: Booster vaccination with MenACWY-CRM elicited a robust immune response during the 2-year follow-up period, irrespective of previous vaccination. SN - 1532-0987 UR - https://www.unboundmedicine.com/medline/citation/24911896/Antibody_persistence_after_primary_and_booster_doses_of_a_quadrivalent_meningococcal_conjugate_vaccine_in_adolescents_ DB - PRIME DP - Unbound Medicine ER -